INOVIQ (IIQ.AX) Stock Analysis & Winston Score

INOVIQ Ltd is an Australian biotechnology company focused on developing diagnostic tests and drug delivery tools for cancer and other serious diseases. Its core work involves two main areas: cancer detection tests that use blood samples to find disease early, and a nanotechnology platform called SUVs (Subunit Vesicles) designed to deliver drugs more effectively inside the body. The company sells to or partners with research institutions, hospitals, and pharmaceutical companies. INOVIQ generates revenue through research collaborations, licensing agreements, and early-stage product sales, though it currently spends far more than it earns — reflected in its deeply negative margins. The company operates primarily in Australia with ambitions to reach global healthcare markets. Its competitive position depends on the uniqueness of its nanotechnology and diagnostic intellectual property, which is still being validated through clinical studies. The key risk is that INOVIQ remains pre-revenue at scale, meaning it must continue raising capital while waiting for its products to clear regulatory and commercial hurdles.